openPR Logo
Press release

Dendrimers and Polymer Drugs Conjugate Market Detailed Study Analysis with Forecast by 2026 - Starpharma Holdings, AstraZeneca, Eli Lilly, Nektar Therapeutics, Dade Behring

05-30-2019 04:10 PM CET | Health & Medicine

Press release from: Coherent Market Insights

Dendrimers and Polymer Drugs Conjugate

Dendrimers and Polymer Drugs Conjugate

Dendrimers, and polymer drug conjugates are nano–sized medicines used for therapeutic applications. In polymer drug conjugates, polymers are covalently bonded to the drug molecule and the linkers are biologically active. Dendrimers are highly water soluble, polyvalent, and have precise molecular weight. They act as carriers of drugs, and facilitate their administration in the body. Dendrimers also have other applications in diagnostic analyses, target therapy, and vaccines. They are also used for the treatment of cancer. Other commercially available polymer drug conjugates include VivaGel, Dendrimer – docetaxel, and Dendrimer – oxaliplatin among others.

Global Dendrimers and Polymer Drugs Conjugate Market Drivers

Product launches, and collaboration activities of manufacturers are expected to boost the global dendrimers and polymer drugs conjugate market growth. For instance, in April 2019, VivaGel was officially launched in Australia by Aspen Pharmacare and commercialized by Starpharma. Vivagel is used for the treatment of bacterial vaginosis, a non-antibiotic therapy. It contains astodrimer sodium which is a type of dendrimer. It is the only treatment which is available over the counter, i.e., without prescription. Such partnerships are expected to propel the growth of global dendrimers and polymer drugs conjugate market. Furthermore, in September 2015, AstraZeneca entered a license agreement with Starpharma Holdings Limited. AstraZeneca used their DEP technology, a type of dendrimer drug delivery system, to study several cancer compounds in the early phases of development.

Ask For Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/2628

Global Dendrimers and Polymer Drugs Conjugate Market Regional Analysis

North America is expected to be the dominant region in the global dendrimers and polymer drugs conjugate market. Presence of manufacturers like Eli Lilly & Co., Dade Behring and Nektar Therapeutics, potential customer base, and frequent research and development activities by key players is expected to drive North America dendrimers and polymer drugs conjugate market growth. For instance, in November 2016, Nektar Therapeutics commenced its investigational study on NKTR-102. The drug is being studied for the treatment of metastatic breast cancer. It contains irinotecan (dendrimer)/ Topoisomerase I inhibitor, and is currently in the third phase of clinical trial. Such key research and development activities are expected to drive the global dendrimers and polymer drugs conjugate market growth.

Global Dendrimers and Polymer Drugs Conjugate Market Taxonomy

The global dendrimers and polymer drugs conjugate market is segmented on the basis of dendrimers type, applications, distribution channel, and region.

By Dendrimers Type
Poly – etherhydroxyethyl amine (PEHAM)
Poly - esterhydroxyethyl amine (PEA)
Poly - amido amine (PAMAM)
Poly – L – lysine
Poly – propylene imine
Others

Global Dendrimers and Polymer Drugs Conjugate Market Restraints

Disadvantages associated with employment of dendrimers and polymer conjugated drugs may hamper the global dendrimers and polymer conjugate market growth. Dendrimers are used in pharmaceutical industry, however their biological use is restricted due to their toxicity. The interaction between the positive charge present on the surface area of dendrimers and the negative charge present on the biological membrane leads to membrane erosion and thinning. It disrupts the membrane and can cause cytotoxicity, hematological toxicity and hemolytic toxicity. Hence, this factor may restrain the use of dendrimers and polymers in potential pharmaceutical applications, and also hinder the global dendrimers and polymer drugs conjugate market growth.

Global Dendrimers and Polymer Drugs Conjugate Market Key Players

Some of the major players operating in the global dendrimers and polymer drugs conjugate market include, Starpharma Holdings Ltd., AstraZeneca Plc., Eli Lilly & Co., Nektar Therapeutics, Dade Behring, Stiefel Laboratories, Cerulean Pharma Inc., Merck KGaA, Qiagen and CTI Biopharma Corp.

Download The PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/2628

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Dendrimers and Polymer Drugs Conjugate Market Detailed Study Analysis with Forecast by 2026 - Starpharma Holdings, AstraZeneca, Eli Lilly, Nektar Therapeutics, Dade Behring here

News-ID: 1759821 • Views: 1704

More Releases from Coherent Market Insights

The Global Cold Cough And Sore Throat Remedies Market Is Witnessing High Demand …
One of the most common complications from cold cough and sore throat is the inability to breathe properly. For the most part, this is usually brought on by congestive heart failure. Another common complication from influenza is the development of pneumonia, which increases the risks of infection and increases the risk of death. Some other complications from influenza include the development of Guillain Barre Syndrome and the paralytic podium symptoms. It
Flavoxate Hydrochloride Tablets Market to Witness Significant Growth, Owing to H …
Flavoxate HCL is a synthetic urinary tract spasmolytic used to treat bladder symptoms such as frequent or urgent urination, increased nighttime urination, bladder pain, and incontinence (urine leakage). According to International Continence Society, in 2018, 63 million people suffered from urgency urinary incontinence worldwide. Such high prevalence of incontinence is expected to aid in growth of the flavoxate hydrochloride tablets market. High prevalence of urinary tract infections (UTIs) is also expected
The Synthetic Hormones Market Is Rapidly Expanding Due To The High Prevalence Of …
Synthetic Hormones have enabled people with all kinds of ailments to live normal lives again. For centuries, synthetic Hormones have been used in a variety of applications by both men and women for various purposes. The earliest usage of Hormone was to prevent and treat ailments associated with reproduction, such as infertility problems and birth defects. Since then synthetic Hormones have been extensively used to treat many non-related ailments. When
North America & Europe Artificial Pancreas Systems Market Continues To Expand Ra …
Artificial Pancreas Systems have come a long way since their inception and many advancements have been made. In the past artificial pancreas was used primarily to treat diabetes. However, today there are many other conditions that mimic or even correct diabetes and this includes chronic renal failure disease (CRF). CRF is caused by a shortage in the body's natural ability to produce insulin or sugar. The primary factor aiding the

All 5 Releases


More Releases for Dendrimer

CD Bioparticles Expands Its Biodegradable Polymers Portfolio with Dendrimers
As a leading manufacturer and supplier of various drug delivery products and services, CD Bioparticles recently introduces a series of dendrimers for research use, such as DMPA-G1-TMP-Acetylene, DMPA-G1-TMP-Azide, DMPA-G1-TMP-Carboxyl, and DMPA-G1-TMP-NHBOC. These biodegradable polymers can be used in theranostics, biosensors, optics, adhesives and coatings. With customized delivery strategies, precise designs and modifications of drugs or drug-contained cargos, and advanced technical platforms, CD Bioparticles can help scientists to solve problems in the
Nanopharmaceuticals Market Global Industry Insights by Abbott, GlaxoSmithKline p …
Key players in the market are focused on research and development of nanopharmaceuticals in order to develop novel products to address the critical unmet needs of patients. According to the P&T Community Journal, December 2017, DTXSPL8783, dendrimer for cancer treatment is being investigated, which is in clinical trials of phase 1 study, for patients with advanced cancer. Get PDF Sample Copy of this Report @ www.coherentmarketinsights.com/insight/request-sample/2485 Similarly, Vivagel developed by Starpharma, is
Future Growth of Nanopharmaceuticals Market –Novel Approach for Cancer Treatme …
Key players in the market are focused on research and development of nanopharmaceuticals in order to develop novel products to address the critical unmet needs of patients. According to the P&T Community Journal, December 2017, DTXSPL8783, dendrimer for cancer treatment is being investigated, which is in clinical trials of phase 1 study, for patients with advanced cancer. Get PDF Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/2485 Similarly, Vivagel developed by Starpharma, is
Nanopharmaceuticals Market Revenue Opportunies By Key Vendors Novartis AG, Pfize …
Key players in the market are focused on research and development of nanopharmaceuticals in order to develop novel products to address the critical unmet needs of patients. According to the P&T Community Journal, December 2017, DTXSPL8783, dendrimer for cancer treatment is being investigated, which is in clinical trials of phase 1 study, for patients with advanced cancer. Download PDF Brochure @ www.coherentmarketinsights.com/insight/request-pdf/2485 Similarly, Vivagel developed by Starpharma, is in phase 3 clinical
Incredible Growth of +22.1% CAGR for Nanopharmaceuticals Market is Thriving Worl …
Key players in the market are focused on research and development of nanopharmaceuticals in order to develop novel products to address the critical unmet needs of patients. According to the P&T Community Journal, December 2017, DTXSPL8783, dendrimer for cancer treatment is being investigated, which is in clinical trials of phase 1 study, for patients with advanced cancer. Download PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/2485 Similarly, Vivagel developed by Starpharma, is in phase 3 clinical
Nanopharmaceuticals Market Research and Development by Market Top Key Players No …
Key players in the market are focused on research and development of nanopharmaceuticals in order to develop novel products to address the critical unmet needs of patients. According to the P&T Community Journal, December 2017, DTXSPL8783, dendrimer for cancer treatment is being investigated, which is in clinical trials of phase 1 study, for patients with advanced cancer. Download PDF Brochure @ http://bit.ly/2T70IQi Similarly, Vivagel developed by Starpharma, is in phase 3 clinical